New­ly de­buted biotech shoots for $40M IPO; In­tel­lia touts new an­i­mal da­ta on CRISPR/Cas9

⇨ Just 8 months af­ter mak­ing its de­but at the be­gin­ning of the year, Cam­bridge, MA-based Cue Bio­phar­ma has filed for a $40 mil­lion IPO. The TCR com­pa­ny is based on work done at Al­bert Ein­stein Col­lege of Med­i­cine. The biotech win­dow has opened con­sid­er­ably in the last few months, but a fledg­ling com­pa­ny like this could well test in­vestors’ ap­petite for the un­known. Ac­cord­ing to the S-1, they’re still in­volved in pre­clin­i­cal work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER